WALTHAM,
Mass., Nov. 25, 2024 /PRNewswire/ -- Spyre
Therapeutics, Inc. (NASDAQ: SYRE), a clinical-stage biotechnology
company utilizing best-in-class antibody engineering, rational
therapeutic combinations, and precision medicine approaches to
target improved efficacy and convenience in the treatment of
Inflammatory Bowel Disease ("IBD"), today announced that will
participate in a fireside chat and investor meetings at the 7th
Annual Evercore ISI HealthCONx Conference. Details of the fireside
are as follows:
- Tuesday, December 3, 2024, at
7:30 a.m. Eastern time
To access this webcast, please visit the "Events &
Presentations" page within the Investors section of the Spyre
website at ir.spyre.com. An archive of the webcast will be
available for replay following the end of the conference.
About Spyre Therapeutics
Spyre Therapeutics is a clinical-stage biotechnology company
that aims to create next-generation inflammatory bowel disease
(IBD) products by combining best-in-class antibody engineering,
rational therapeutic combinations, and precision medicine
approaches. Spyre's pipeline includes extended half-life antibodies
targeting α4β7, TL1A, and IL-23. For more information, visit
Spyre's website at www.spyre.com.
Follow Spyre Therapeutics on social media: @spyretx and
LinkedIn
View original content to download
multimedia:https://www.prnewswire.com/news-releases/spyre-therapeutics-to-participate-in-the-7th-annual-evercore-isi-healthconx-conference-302315865.html
SOURCE Spyre Therapeutics, Inc.
